 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Stockwinners Market Radar for December 26, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service |
| MA... | Hot Stocks20:04 EST Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. According to Mastercard (MA) SpendingPulse, U.S. retail sales excluding automotive increased 7.6% year-over-year this holiday season, running from November 1 through December 24. Mastercard SpendingPulse measures in-store and online retail sales across all forms of payment and is not adjusted for inflation. Online sales grew 10.6% compared to the same period last year, the preliminary insights show. This holiday season, e-commerce made up 21.6% of total retail sales, up from 20.9% in 2021 and 20.6% in 2020. The channel continues to experience elevated growth as consumers prioritize convenience and availability of discounts. 2. Apple (AAPL) Japan is being charged $98M in additional taxes by Tokyo authorities, apparently for bulk sales of iPhones and other devices to foreign tourists that were incorrectly exempted from the consumption tax, Nikkei's Tomoshizu Kawase and Konori Fujita report. Bulk purchases of iPhones by foreign shoppers were discovered at some Apple stores, a source said. At least one transaction involved an individual buying hundreds of handsets at once, suggesting that the store missed taxing a possible reseller. 3. Nio (NIO) founder and Chief Executive Officer William Li said the Chinese EV maker may face a challenging first half as a cut in government subsidies and the broader economic slowdown erode local demand in the world's largest new-energy vehicle market, according to Bloomberg. Customers are likely to try place orders before the end of the year, when the national subsidies for electric vehicles are expected to be phased out, Li said at a briefing after the company's launch of its latest models at a weekend event in Hefei, central China. 4. Disney's (DIS) "Avatar: The Way of Water" won this year's storm-challenged Christmas weekend, with Storm Elliott bringing freezing temperatures, high winds, and snow. Revenue for Christmas Day is estimated to be at $44M, according to Comscore, the worst showing in the last 20 years, excluding 2020. "Avatar: The Way of Water" placed number 1 at the domestic box office with an estimated $90M for the four-day holiday weekend. Overseas, the movie grossed $168.6M for the three-day period for a foreign cume of $601.7M. 5. Costo (COST), Pfizer (PFE), Moderna (MRNA), GSK (GSK), and Sanofi (SNY) saw positive mentions in this week's edition of Barron's.
|
| PTON | Hot Stocks14:53 EST Peloton to offer refurbished bikes with Peloton Certified Refurbished - Peloton has announced its new refurbished bikes program, Peloton Certified Refurbished. This new offering is available across the continental U.S. and in Canada. Starting December 26, the refurbished Peloton Bike/ Bike+ will be available to buy online or in showrooms, with full delivery and setup included with each purchase: Refurbished Peloton Bike for $1,145, representing savings of $300 compared to a new Peloton Bike; and Refurbished Peloton Bike+ for $1,995, representing savings of $500 compared to a new Peloton Bike+. The company noted that every refurbished product is thoroughly inspected, cleaned and tested to ensure it meets Peloton standards, and is backed by the same 12-month limited warranty that comes with new bikes. Peloton Certified Refurbished bikes include the same features as a new Peloton Bike/Bike+, including access to Peloton's variety of classes, instructors, disciplines, and music through your All Access Membership.
|
| MA | Hot Stocks14:29 EST Mastercard SpendingPulse shows U.S. retail sales Grew 7.6% this holiday season - According to Mastercard SpendingPulseTM, U.S. retail sales excluding automotive increased 7.6% year-over-year this holiday season, running from November 1 through December 24. Mastercard SpendingPulse measures in-store and online retail sales across all forms of payment and is not adjusted for inflation. Online sales grew 10.6% compared to the same period last year, the preliminary insights show. This holiday season, e-commerce made up 21.6% of total retail sales, up from 20.9% in 2021 and 20.6% in 2020. The channel continues to experience elevated growth as consumers prioritize convenience and availability of discounts. Black Friday sustains its title as the top spending day of the 2022 holiday season, up +12% year-over-year excluding automotive. This was followed closely by Saturdays in December. Building on the ongoing demand for experiences, in-person dining continued to show strong momentum with restaurants up 15.1% year-over-year. From gatherings with co-workers to dinners out with friends and family, the festive season brought consumers out for the holidays.
|
| CHRS | Hot Stocks14:24 EST Coherus, Junshi Biosciences share update on FDA Review of BLA for Toripalimab - Shanghai Junshi Biosciences and Coherus BioSciences announced that the companies have not received an action letter from the U.S. Food and Drug Administration regarding the Biologics License Application, or BLA, for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma by the Prescription Drug User Fee Action date of December 23, 2022. The FDA previously communicated that an on-site inspection of Junshi Biosciences' manufacturing facility for toripalimab is required before the Agency can approve the application; however, they were unable to conduct the inspection during the current review cycle due to the ongoing impact of COVID-19 related restrictions on travel in China. The BLA for toripalimab remains under review, and Junshi Biosciences and Coherus are engaged in ongoing discussions with the Agency about the pre-approval inspection plans. The FDA has granted priority review for the toripalimab BLA for use in combination with gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic NPC and for toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy. Recurrent or metastatic NPC is an aggressive head and neck tumor which has no FDA-approved treatment options.
|
